Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 11/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.45 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.39 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KLK6 | Q92876 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3833639 | 0.92 | SLC16A1 (0.44) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL4918902 | 0.91 | SLC16A1 (0.55) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3868024 | 0.87 | SLC16A1 (0.44) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3833088 | 0.86 | SLC16A1 (0.43) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3828214 | 0.86 | SLC16A1 (0.43) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3829925 | 0.85 | SLC16A1 (0.65) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL3829995 | 0.83 | SLC16A1 (0.62) | SLC16A1CYP2C9CYP3A4SLC16A7 | |
| SCHEMBL4801183 | 0.83 | SLC16A1 (0.54) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL4803837 | 0.82 | SLC16A1 (0.44) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 | |
| SCHEMBL14140186 | 0.80 | SLC16A1 (0.40) | SLC16A1CYP2C9CYP3A4SLC16A7SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414825-B9 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| EP-1414825-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | TPMT, CBR1, CYP2D6 | SLC16A1 3284/4885CYP2C9 89/4885CYP3A4 93/4885 |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | C5, TPMT, C9 | SLC16A1 3369/4885CYP2C9 71/4885CYP3A4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.